Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
reozalimab
- Development stage
- Phase 2
- Lead developer
- Innovent Biologics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Reozalimab (IBI318) is a first-in-class recombinant IgG1 bispecific antibody designed to simultaneously target programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1). Developed by Innovent Biologics in collaboration with Eli Lilly, it functions as a checkpoint inhibitor to restore and enhance T-cell mediated anti-tumor immune responses. By blocking both the receptor and its ligand, reozalimab aims to provide superior efficacy compared to single-target monoclonal antibodies. It is primarily being investigated for the treatment of advanced malignancies, including small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and nasopharyngeal carcinoma, often in combination with chemotherapy.
- Brand names
- reozalimab
- Other names
- IBI 318IBI318IBI-318LY3434172LY-3434172LY 3434172
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on reozalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on reozalimab.